Syngene International Ltd. (NSE: SYNGENE, BSE: 539268) is a Bengaluru, Karnataka-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹15,371 Cr, it ranks #443 by market cap among the 6,137 Indian listed companies on FinBizNet, and #6 of 11 in Pharmaceutical CDMO and CRO Services. At ₹366.85 (as of 25 Oct 2026), the share price is 46.0% below its 52-week high of ₹678.95 and 6.5% above its 52-week low of ₹344.45. The share price is down 42.7% over one year and down 9.8% over three months.
| Current Price | ₹366.85 |
|---|---|
| Market Cap | ₹15,371 Cr |
| NSE Symbol | SYNGENE |
| BSE Code | 539268 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 50.6 |
| Return on Equity | 6.62% |
| Return on Assets | 4.78% |
| 52-Week Range | ₹344.45 – ₹678.95 |
| 1-Year Price Change | -42.7% |
| 3-Month Price Change | -9.8% |
| Beta (1Y) | -0.07 |
| Dividend Yield | 0.31% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.syngeneintl.com |
| Revenue | ₹736 Cr |
|---|---|
| Net Profit | ₹-9 Cr |
| Net Margin | -1.2% |
| EPS (Basic) | ₹-0.22 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigil
1. Providing Contract Research and Manufacturing Services-This segment provides contract research and manufacturing services. It offers drug discovery, development, and manufacturing services.
1. Providing Contract Research and Manufacturing Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹2,42,758 Cr | 93.8 | 16.19% | ₹3,080 Cr | +35.6% |
| Anthem Biosciences Limited | ₹46,303 Cr | 77.5 | 19.45% | ₹418 Cr | +5.3% |
| Sai Life Sciences Limited | ₹29,513 Cr | 85 | 15.13% | ₹554 Cr | +58.5% |
| Cohance Lifesciences Ltd | ₹17,754 Cr | 97.9 | 5.11% | ₹422 Cr | -49.9% |
| Onesource Specialty Pharma Limited | ₹16,144 Cr | -213 | -1.26% | ₹449 Cr | -27.8% |
| Syngene International Ltd. | ₹15,371 Cr | 50.6 | 6.62% | ₹736 Cr | -42.7% |
| Jubilant Pharmova Ltd | ₹14,958 Cr | 37.3 | 5.96% | ₹2,229 Cr | -12.8% |
| Concord Biotech Ltd | ₹14,008 Cr | 51.7 | 13.54% | ₹257 Cr | -19.5% |
| Blue Jet Healthcare Ltd | ₹9,855 Cr | 35.5 | 19.88% | ₹293 Cr | -29.2% |
Listed by market capitalisation. Ratios are shown for context only.
Syngene International Ltd. is trading at ₹366.85, with a market capitalisation of ₹15,371 Cr.
Syngene International Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Syngene International Ltd. has a P/E of 50.6 and a return on equity of 6.62%.
Syngene International Ltd. is listed on the NSE under the symbol SYNGENE and on the BSE under the scrip code 539268.
Syngene International Ltd.'s share price is down 42.7% over one year and down 9.8% over three months. Its 52-week range is ₹344.45 to ₹678.95.
In Q1 FY27, Syngene International Ltd. reported revenue of ₹736 Cr and net profit of ₹-9 Cr, with basic EPS of ₹-0.22 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.